The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech, and Genmab are expected to transform treatment options. The U.S. leads the market, with KEYTRUDA generating the highest revenue in 2025. Advances in targeted therapies and personalized medicine are also fueling growth, alongside expanding clinical trials and regulatory approvals.
Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL trial, testing a treatment to prevent cytokine release syndrome in multiple myeloma patients receiving teclistamab. The trial has expanded to University College London Hospital with m...
Last week, US stock markets gained ground with the S&P 500 up 1.2% and Nasdaq Composite rising 1.7%, despite President Trump's announcement that the cease-fire with Iran had ended. Investors appeared to focus on ongoing US-Iran talks rather than the ...
